Pros and cons of subcutaneous (SC) versus intravenous (IV) administration of immune checkpoint inhibitors in non-small cell lung cancer
Julie Moeller, Michael D. Green, Nithya Ramnath
Topics & Concepts
MedicineLung cancerImmune systemImmunotherapyCancerCancer researchOncologyImmunologyInternal medicineCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Research Studies